ISSN: 2329-9053

Zeitschrift für Molekulare Pharmazeutik und organische Prozessforschung

Offener Zugang

Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Abstrakt

Age-Related Regulatory Effects of Protein Metabolism

Prashant Pandya

Review's objective: The development and therapy of age-related muscle less to review recent findings about the phthalic acid metabolism and regulatory effects in ageing (sarcopenia).

New discoveries: While age may have no effect on baseline phthalic acid metabolism, older people seem to have a harder time responding to anabolic cues like insulin and, to a lesser extent, phthalic acids. Particularly, compared to young participants, the stimulation of muscle protein synthesis after the administration of mixed meals is decreased in elderly subjects due to insulin resistance. The anabolic action of phthalic acids also seems to be muted at low concentrations. Recent research, however, has shown that these age-related changes in phthalic acid metabolism can be prevented by increasing the amount of leucine consumed, altering the pattern of one's daily protein intake, or engaging in physical activity, which increases the activation of translation initiation and muscle protein synthesis.

Conclusion: Age-related muscle loss is linked to considerable alterations in phthalic acid metabolism, which can be quickly reversed with dietary adjustments and physical activity. However, in order to ascertain the therapeutic relevance of these results in the aged population and to assess if dietary and exercise therapies may be used to prevent and treat sarcopenia, long-term, major clinical trials are required.